Key Takeaways
- Strong H1, cautious H2 guide: Revenue grew double digits in H1 and H2 is expected to do the same, yet management held its full-year EBITDA margin guidance at 32–35% despite H1 printing ~40%.
- Backward integration is paying off: Net material consumption fell from 40% to 32% of sales, driven by the Unit 3 Kakinada plant, a structural cost improvement that also protects the supply chain.
- Three big bets are about to convert: One of the three major dedicated investment projects is very close to commercialization; the other two are expected to follow over the next one or two quarters.
- Peptide ambition is real but details are scarce: Management says futuristic capacity will make Divi's a top-three global player, but declined to quantify installed capacity, customer geography, or asset turns, citing NDAs.
- What to watch next quarter: Commercialization of the first dedicated project, any update on regulatory inspections for the three major programs, and whether the H2 margin mix can sustain the H1 run rate.
The Margin Story: Cost Structure Is Improving Faster Than Guidance Admits
- Net material consumption dropped 800 bps: The ratio fell from 40% to 32% of sales revenue in H1, a structural shift driven by two forces: a slightly higher Custom Synthesis mix, and heavy backward integration at the Unit 3 Kakinada plant that is yielding both cost benefits and supply chain protection.
- Unit 3 is the engine: The Kakinada facility is assuming a larger role in the production network, supporting backward integration through selected pre-chemistry operations and enabling phased transfer of manufacturing from existing facilities, which frees up space and creates additional capacity for critical raw materials.
- Input costs remain a headwind: Petrochemical-based solvent prices stayed elevated during the quarter, and logistics costs rose on both ocean freight (Red Sea rerouting extended transit times) and air freight (fuel prices, airspace restrictions, reduced carrier capacity).
- Mitigation is working: A diversified supplier network, advanced procurement planning, and a rolling three-month inventory coverage for critical materials prevented supply disruption.
- Guidance stayed conservative: Despite H1 EBITDA margins of ~40%, management explicitly declined to raise the 32–35% full-year guidance, calling the higher run rate aspirational but not committed.
Nilima Prasad Divi: "Now, why is it 32% from 40%? I think multiple reasons. One, yes, the CS is slightly higher than what it used to be. But also you need to realize we went into backward integration heavily in the Unit 3 Kakinada plant. And over there, we would say we are trying to make sure our supply chain is protected. Along with that, we do see certain cost benefits even over there."
The Three Big Projects: Commercialization Is Now Close
- One project is near the finish line: Management stated that one of the three major dedicated investment projects is very close to commercialization.
- The other two are quarters away: The remaining two projects are expected to see the commercialization factor come in over the next one or two quarters.
- Validations are done: All three projects have completed their validation activities, and the company has supplied validation quantities to customers, who must now complete their own qualification processes before submitting batches to regulators.
- Regulatory timing is the wildcard: Divi's has not yet received notice on whether the agency will conduct a pre-approval inspection or clear the file based on previous history; that will only be known after customers qualify and submit the batches.
- Dedicated means binary utilization: Once approvals come, these facilities will be fully utilized because they are built with specialized equipment that can only be used for that specific product, so the revenue ramp should be sharp.
- The pipeline beyond the big three: Divi's handles about 60–70 projects at any given time across all phases, with several already validated and commercialized, and others progressing through validation. The time cycle for Phase II/III molecules to move to commercialization has its own rhythm.
Dr. Kiran S. Divi: "Till now, we did not receive any notice on either of them. But as the validation batches go to our customers and they qualify us, then they submit the batches, it is then that we would know whether they would need an inspection or if they would clear the file based on previous history."
Peptides: A Top-Three Ambition, Light on Proof Points
- The stated ambition is large: Management claims that with futuristic capacity, Divi's will be among the top three players globally in peptides.
- Capacity is being built now: Several 3,000-litre SPPS lines are currently being installed to meet requirements of programs being worked on, with more lines being added based on customer interest.
- The business is innovation-only: Divi's does not make generic peptides; the entire peptide business is strictly for innovation, serving innovator pharma companies under CDMO arrangements.
- Vertical integration is a differentiator: The company has built a manufacturing platform that spans from peptide building blocks to dipeptides, tripeptides, and large peptide fragments, with several products currently under validation or progressing through customer qualification.
- Liquid-phase capacity is effectively unlimited: For liquid-phase peptide work, the company can use existing pilot plants with regular small-volume reactors, so no capacity constraint exists there.
- Purification capability exists but is not yet deployed at scale: Divi's has a center of excellence for integrated peptides with gram-scale purification capability, and will look at larger-scale purification when customers feel the opportunity will go to commercialization.
- Management declined to quantify almost everything: No disclosure on total SPPS capacity installed, customer geography split, asset turns, or the in-house versus bought-in split for resins and amino acids, all citing NDAs.
Dr. Kiran S. Divi: "If I say that, it will put me in trouble because I have NDA in place. All I will say is, with the futuristic capacity, we will be in the top three players."
Cash Flow & Working Capital: The Capex Cycle Is Consuming Cash
- Cash flow from operations halved YoY: CFO declined 50% to ₹959 crores in H1, even as PBT grew 50–60%, because the company is in a large capex cycle with huge capitalization of ~₹700+ crores this quarter and CWIP of ~₹1,638 crores where advances have been disbursed.
- Inventory built deliberately: Finished goods and WIP increased by ₹1,197 crores in H1, driven by three factors: stocking three months of critical raw materials due to Middle East geopolitical issues, escalation in some critical raw material prices, and volume of material stocked at various stages to ensure uninterrupted production and on-time delivery.
- Management declined to break out how much of the inventory build is for dedicated projects awaiting customer approval, or what offtake protections exist if approvals are delayed.
- Capex is running at ~₹2,000 crores per year: Management expects this level, plus or minus 20%, to continue for the next two to three years, based on increasing RFPs, customer interest, and growing confidence year on year.
- No capacity shortage is foreseen: The company does not actively invest into capacity until it sees opportunity, because everything is planned in advance with long-term contracts in place, especially on the Custom Synthesis side.
Demand & Growth: Broad-Based, with Custom Synthesis Leading
- Every segment is growing: Small molecule, peptide, nutraceuticals, and generics all grew pretty well during the quarter.
- Custom Synthesis is the growth driver: Customer engagement remains strong, with several programs advancing through different stages of development and commercialization, and validation quantities supplied for select projects during the quarter.
- Growth is not solely from new validation batches: Several molecules worked on and validated in the past have slowly been commercialized and are now contributing, reflecting Divi's 30-year history of working on multiple products.
- Generics saw volume growth: The generics business recorded a slight increase in usage and volume, which management characterized as good, though pricing pressure persists.
- Nutraceuticals benefit from a macro tailwind: Increasing global emphasis on preventive healthcare, wellness, and scientifically validated ingredients is creating growth opportunities, and the company is expanding capabilities to address evolving customer requirements.
- Technology deployment is deepening: Flow chemistry and biocatalysis platforms are being strengthened, with biocatalysis infrastructure expanding to support ton-scale manufacturing using multiple enzymes, and these technologies are being progressively deployed across selected products and processes.
- H2 revenue growth is expected to be double-digit, though management would not specify whether closer to 10% or 20%.
Dr. Kiran S. Divi: "See, peptide itself is a very complex chemistry. Manufacturing itself requires a lot of know-how and a lot of automation, a lot of technology. The whole synthesis and the process, either it is fragments or it is a finished product all the way downstream, and then you are talking about API, everything has its own challenge."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| First dedicated project commercialization | One of three major dedicated investment projects is very close to commercialization | Imminent (no date given) |
| Remaining two dedicated projects | Expected to see commercialization factor come in | Next one to two quarters |
| H2 FY27 revenue growth | Double-digit growth | H2 FY27 |
| Full-year capex | ~₹2,000 crores, plus or minus 20% | FY27 |
| Medium-term capex run rate | ₹2,000 crores plus or minus 20% year on year, based on increasing RFPs and customer interest | Next two to three years |
| EBITDA margin | 32–35% (guidance held despite H1 at ~40%) | FY27 |
| Peptide global position | Top three players globally with futuristic capacity | No date (capacity being installed) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated total income | ₹3,770 cr, +32% YoY from ₹2,860 cr |
| Profit before tax | ₹1,505 cr, +65% YoY from ₹912 cr |
| Profit after tax | ₹1,127 cr, +64% YoY from ₹689 cr |
| H1 FY27 consolidated total income | ₹6,907 cr, vs ₹5,389 cr in H1 FY26 |
| H1 FY27 profit after tax | ₹2,029 cr, +64% YoY from ₹1,234 cr |
| H1 FY27 constant currency revenue growth | 17% YoY |
| H1 FY27 revenue mix: generics / custom synthesis | 38% generics, 62% custom synthesis |
| H1 FY27 nutraceutical revenue | ₹571 cr, vs ₹492 cr in H1 FY26 |
| H1 FY27 net material consumption | ~32% of sales revenue, vs 40% in H1 FY26 |
| H1 FY27 net forex gain | ₹20 cr, vs gain of ₹103 cr in H1 FY26 |
| Assets capitalized in Q2 FY27 | ₹772 cr; H1 FY27 total: ₹1,223 cr |
| Capital work in progress | ₹1,638 cr as of Sep 30, 2026 |
| Cash balances | ₹2,181 cr as of Sep 30, 2026 |
| Trade receivables | ₹3,705 cr as of Sep 30, 2026 |
| Inventories | ₹5,325 cr as of Sep 30, 2026 |
| H1 FY27 cash flow from operations (pre-tax) | ₹959 cr, declined 50% YoY |
| Overall asset turnover | ~1.5x |
| H1 FY27 finished goods and work-in-progress build-up | ₹1,197 cr |
| CDMO business YoY growth | ~50% in Q2 FY27, similar to Q1 FY27 growth in the 40s (per an analyst's math) |
| Annual capex outlook | ~₹2,000 cr, plus or minus 20%, for the next few years |
| CSR: daily access to clean drinking water | >13 lakh individuals |